Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Recruiting · NCT05554939 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT05554939 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese PLA General Hospital | 238 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Biotherapeutic Department, Chinese PLA General Hospital | Beijing | China | 2 |
| School of phamaceutical, Tsinghua University | Beijing | China | 1 |